Vanaken Lize, Landini Nicholas, Lenaerts Joris, Claeys Eveline, Lenaerts Jan, Wuyts Wim A, Verschakelen Johny, De Langhe Ellen
Division of Rheumatology, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium.
Department of Radiology, Ca'Foncello General Hospital, Piazzale Ospedale, 1, 31100, Treviso, Italy.
Clin Rheumatol. 2020 Nov;39(11):3393-3400. doi: 10.1007/s10067-020-05105-4. Epub 2020 May 8.
In systemic sclerosis, baseline extent of radiological involvement is an important outcome predictor and baseline absence of radiological involvement suggests a more favourable prognosis. As current predictive models are based on cohorts with variable disease duration, we aim to assess disease dynamics in early disease.
Patients were included from the prospective longitudinal Belgian Systemic Sclerosis Cohort. We included patients with a disease duration < = 36 months at baseline with available baseline thoracic high-resolution computed tomography (HRCT) images and longitudinal pulmonary function test (PFT) results until 42 months of follow-up.
Fifty-two patients were included; 50% were male and 44% suffered from diffuse cutaneous systemic sclerosis. A total of 46% carried anti-topoisomerase 1 antibodies. The mean disease duration at baseline visit was 11 months. At baseline visit, 40.4% (21/52) patients had HRCT abnormalities. Patients with abnormal HRCT findings more frequently suffered from diffuse cutaneous systemic sclerosis (p < 0.05) and less frequently carried anti-centromere antibodies (p < 0.05). Patients without CT abnormalities at baseline had a shorter disease duration (9 ± 7 months versus 14 ± 12 months). After 42 months, 8/52 patients, including 3 patients with normal HRCT findings at baseline, died due to SSc-related manifestations. Progression of lung fibrosis occurred in 16 patients at month 42, including 7 patients with normal CT at baseline. No clear predictors of progression could be identified.
In early SSc patients, the disease dynamics differ from the large published cohorts. Progressive lung fibrosis and mortality can also occur in patients without radiological abnormalities at baseline. Key Points • Disease dynamics in early SSc differ from more established SSc. • In early SSc, progressive pulmonary fibrosis can occur in patients without CT abnormalities at baseline. • In early SSc, more stringent pulmonary follow-up is warranted both in lcSSc and dcSSc.
在系统性硬化症中,放射学累及的基线范围是一个重要的预后预测指标,而基线时无放射学累及提示预后更佳。由于目前的预测模型基于疾病病程各异的队列,我们旨在评估疾病早期的动态变化。
患者来自前瞻性纵向比利时系统性硬化症队列。我们纳入了基线时疾病病程≤36个月、有可用的基线胸部高分辨率计算机断层扫描(HRCT)图像以及直至随访42个月的纵向肺功能测试(PFT)结果的患者。
共纳入52例患者;50%为男性,44%患有弥漫性皮肤型系统性硬化症。共有46%携带抗拓扑异构酶1抗体。基线访视时的平均疾病病程为11个月。在基线访视时,40.4%(21/52)的患者有HRCT异常。HRCT结果异常的患者更常患有弥漫性皮肤型系统性硬化症(p<0.05),携带抗着丝点抗体的频率更低(p<0.05)。基线时CT无异常的患者疾病病程较短(9±7个月对14±12个月)。42个月后,52例患者中有8例死亡,包括3例基线时HRCT结果正常的患者,死因均为与系统性硬化症相关的表现。42个月时,16例患者出现肺纤维化进展,其中7例基线时CT正常。未发现明确的进展预测因素。
在早期系统性硬化症患者中,疾病动态变化与已发表的大型队列不同。基线时无放射学异常的患者也可能发生进行性肺纤维化和死亡。要点 • 早期系统性硬化症的疾病动态变化与更成熟的系统性硬化症不同。 • 在早期系统性硬化症中,基线时CT无异常的患者可能发生进行性肺纤维化。 • 在早期系统性硬化症中,局限性皮肤型系统性硬化症和弥漫性皮肤型系统性硬化症均需进行更严格的肺部随访。